Skip to main content
. 2020 Sep 12;148(4):868–875. doi: 10.1002/ijc.33266

FIGURE 1.

FIGURE 1

Consort diagram of patients diagnosed between April 2010 and December 2017 in England who received ipilimumab, nivolumab, ipinivo and pembrolizumab as first‐line treatment for metastatic melanoma [Color figure can be viewed at wileyonlinelibrary.com]